Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Enterprise Value (2016 - 2025)

Vanda Pharmaceuticals' Enterprise Value history spans 16 years, with the latest figure at -$263.8 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 29.57% year-over-year to -$263.8 million; the TTM value through Dec 2025 reached -$263.8 million, up 29.57%, while the annual FY2025 figure was -$263.8 million, 29.57% up from the prior year.
  • Enterprise Value for Q4 2025 was -$263.8 million at Vanda Pharmaceuticals, down from -$223.7 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$223.7 million in Q3 2025 and bottomed at -$501.5 million in Q1 2023.
  • The 5-year median for Enterprise Value is -$395.3 million (2021), against an average of -$388.7 million.
  • The largest annual shift saw Enterprise Value dropped 21.08% in 2021 before it skyrocketed 41.87% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$432.8 million in 2021, then decreased by 7.87% to -$466.9 million in 2022, then grew by 16.83% to -$388.3 million in 2023, then increased by 3.51% to -$374.6 million in 2024, then grew by 29.57% to -$263.8 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Enterprise Value are -$263.8 million (Q4 2025), -$223.7 million (Q3 2025), and -$244.6 million (Q2 2025).